Skip to main content
. Author manuscript; available in PMC: 2015 Oct 1.
Published in final edited form as: Mol Cancer Ther. 2014 Aug 14;13(10):2264–2275. doi: 10.1158/1535-7163.MCT-14-0291

Figure 6. Both endoglin downregulation and inhibition of Endoglin-GIPC interaction induce differentiation and sensitize pancreatic cancer cells towards gemcitabine.

Figure 6

A. Endoglin downregulation increased E-cadherin expression in ASPC-1 and inhibited Id-1 in both ASPC-1 and MiaPaca-2 cell lines. B. Treatment with 100μmol/L AP1032 inhibited Id-1 in both ASPC-1 and MiaPaca-2 cell lines. C & D. Endoglin downregulation sensitized both ASPC-1 and MiaPaca-2 cell lines towards gemcitabine. E & F. Treatment with 50μmol/L AP1032 sensitized both ASPC-1 and MiaPaca-2 cell lines towards gemcitabine.